Hamilton, Paul T

Plant and Microbial Biology
paul_hamilton@ncsu.edu
919-513-2060
Faculty Profile Login
 

North Carolina is home to a large and growing biotechnology industry.  North Carolina ranks third in the U.S. with over 500 biotechnology companies.  North Carolina State University is situated in close proximity to the Research Triangle Park and NCSU’s Centennial Campus where many of these biotechnology companies are located.

For more than 20 years, I have worked in Research & Development in the biotechnology industry in North Carolina with positions ranging from Scientist to Vice President of R&D.  In these positions, I have had the responsibility of hiring and training scientists and technical staff.  Often, I found that these new hires had little exposure to or understanding of important biotechnology-related business issues involving intellectual property, regulatory affairs, marketing and finance.  Throughout the biotechnology industry, there is a need for employees with a strong technical background along with an understanding of business issues.

The Master’s of Microbial Biotechnology (MMB) program combines science and business training with real-world industry experience.  The real-world experiences, in the form of case study projects and internships, offer students the opportunity to develop the professional skills required for success in industry.  I feel the MMB program provides graduates with business-centric training in biotechnology to become future managers and leaders in the biotechnology industry.

I appreciate the support for the MMB program that has been provided by the biotechnology industry, North Carolina State University and the MMB students both past and present.

 
Expertise:
  Microbiology
Country(s) of experience:
  Denmark |
Type(s) of International Experience:
  Researcher in an international project | Advisor for international students
Projects:
  Substrate specificity testing of recombinant Factor VII using phage display technology
01/01/2012 - 01/01/2016
Funding Agency/Sponsor:
Institutional Partner: Novo Nordisk A/S, Denmark